ID   PLCD1_RAT               Reviewed;         756 AA.
AC   P10688; Q80WI4; Q9QVD3; Q9QVD4; Q9QVD5;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   22-JUL-2015, entry version 163.
DE   RecName: Full=1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1;
DE            EC=3.1.4.11;
DE   AltName: Full=Phosphoinositide phospholipase C-delta-1;
DE   AltName: Full=Phospholipase C-III;
DE            Short=PLC-III;
DE   AltName: Full=Phospholipase C-delta-1;
DE            Short=PLC-delta-1;
GN   Name=Plcd1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3390863; DOI=10.1016/0092-8674(88)90548-X;
RA   Suh P.-G., Ryu S.H., Moon K.H., Suh H.W., Rhee S.G.;
RT   "Cloning and sequence of multiple forms of phospholipase C.";
RL   Cell 54:161-169(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS SHR MET-412; SER-423; ASP-463
RP   AND ALA-668.
RC   TISSUE=Aorta;
RX   PubMed=1684614;
RA   Yagisawa H., Tanase H., Nojima H.;
RT   "Phospholipase C-delta gene of the spontaneously hypertensive rat
RT   harbors point mutations causing amino acid substitutions in a
RT   catalytic domain.";
RL   J. Hypertens. 9:997-1004(1991).
RN   [3]
RP   PROTEIN SEQUENCE OF 50-57; 128-140 AND 728-738.
RC   TISSUE=Brain;
RX   PubMed=1313009;
RA   Kanematsu T., Takeya H., Watanabe Y., Ozaki S., Yoshida M., Koga T.,
RA   Iwanaga S., Hirata M.;
RT   "Putative inositol 1,4,5-trisphosphate binding proteins in rat brain
RT   cytosol.";
RL   J. Biol. Chem. 267:6518-6525(1992).
RN   [4]
RP   PROTEIN SEQUENCE OF 61-76, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   STRAIN=Sprague-Dawley; TISSUE=Hippocampus;
RA   Lubec G., Diao W.;
RL   Submitted (APR-2007) to UniProtKB.
RN   [5]
RP   MUTAGENESIS OF HIS-311; ASN-312; LEU-320; GLU-341; ASP-343; HIS-356;
RP   PHE-360; GLU-390; LYS-438; LYS-440; SER-522; ARG-549; TYR-551 AND
RP   TRP-555.
RX   PubMed=9565585; DOI=10.1074/jbc.273.19.11650;
RA   Ellis M.V., James S.R., Perisic O., Downes C.P., Williams R.L.,
RA   Katan M.;
RT   "Catalytic domain of phosphoinositide-specific phospholipase C (PLC).
RT   Mutational analysis of residues within the active site and hydrophobic
RT   ridge of plcdelta1.";
RL   J. Biol. Chem. 273:11650-11659(1998).
RN   [6]
RP   GLYCOSYLATION AT SER-191 AND THR-193.
RX   PubMed=24098488; DOI=10.1371/journal.pone.0076399;
RA   Cao W., Cao J., Huang J., Yao J., Yan G., Xu H., Yang P.;
RT   "Discovery and confirmation of O-GlcNAcylated proteins in rat liver
RT   mitochondria by combination of mass spectrometry and immunological
RT   methods.";
RL   PLoS ONE 8:E76399-E76399(2013).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 12-130.
RX   PubMed=8521504; DOI=10.1016/0092-8674(95)90219-8;
RA   Ferguson K.M., Lemmon M.A., Schlessinger J., Sigler P.B.;
RT   "Structure of the high affinity complex of inositol trisphosphate with
RT   a phospholipase C pleckstrin homology domain.";
RL   Cell 83:1037-1046(1995).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 205-756.
RX   PubMed=8784353; DOI=10.1038/nsb0996-788;
RA   Grobler J.A., Essen L.-O., Williams R.L., Hurley J.H.;
RT   "C2 domain conformational changes in phospholipase C-delta 1.";
RL   Nat. Struct. Biol. 3:788-795(1996).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 133-756.
RX   PubMed=8602259; DOI=10.1038/380595a0;
RA   Essen L.-O., Perisic O., Cheung R., Katan M., Williams R.L.;
RT   "Crystal structure of a mammalian phosphoinositide-specific
RT   phospholipase C delta.";
RL   Nature 380:595-602(1996).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 133-756, AND CALCIUM-BINDING.
RX   PubMed=9062102; DOI=10.1021/bi962466t;
RA   Essen L.-O., Perisic O., Lynch D.E., Katan M., Williams R.L.;
RT   "A ternary metal binding site in the C2 domain of phosphoinositide-
RT   specific phospholipase C-delta1.";
RL   Biochemistry 36:2753-2762(1997).
CC   -!- FUNCTION: The production of the second messenger molecules
CC       diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is
CC       mediated by activated phosphatidylinositol-specific phospholipase
CC       C enzymes. Essential for trophoblast and placental development.
CC   -!- CATALYTIC ACTIVITY: 1-phosphatidyl-1D-myo-inositol 4,5-
CC       bisphosphate + H(2)O = 1D-myo-inositol 1,4,5-trisphosphate +
CC       diacylglycerol.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC       Note=Binds 3 Ca(2+) ions per subunit. Two of the Ca(2+) ions are
CC       bound to the C2 domain.;
CC   -!- SIMILARITY: Contains 1 C2 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00041}.
CC   -!- SIMILARITY: Contains 2 EF-hand domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00448}.
CC   -!- SIMILARITY: Contains 1 PH domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00145}.
CC   -!- SIMILARITY: Contains 1 PI-PLC X-box domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00270}.
CC   -!- SIMILARITY: Contains 1 PI-PLC Y-box domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00271}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M20637; AAA41886.1; -; mRNA.
DR   EMBL; S74591; AAP31521.1; -; mRNA.
DR   PIR; B28821; B28821.
DR   RefSeq; NP_058731.1; NM_017035.1.
DR   UniGene; Rn.12324; -.
DR   PDB; 1DJG; X-ray; 2.60 A; A/B=133-756.
DR   PDB; 1DJH; X-ray; 2.50 A; A/B=133-756.
DR   PDB; 1DJI; X-ray; 2.50 A; A/B=133-756.
DR   PDB; 1DJW; X-ray; 2.45 A; A/B=133-756.
DR   PDB; 1DJX; X-ray; 2.30 A; A/B=133-756.
DR   PDB; 1DJY; X-ray; 2.80 A; A/B=133-756.
DR   PDB; 1DJZ; X-ray; 2.95 A; A/B=133-756.
DR   PDB; 1MAI; X-ray; 1.90 A; A=11-140.
DR   PDB; 1QAS; X-ray; 2.40 A; A/B=135-756.
DR   PDB; 1QAT; X-ray; 3.00 A; A/B=135-756.
DR   PDB; 2ISD; X-ray; 2.50 A; A/B=133-756.
DR   PDBsum; 1DJG; -.
DR   PDBsum; 1DJH; -.
DR   PDBsum; 1DJI; -.
DR   PDBsum; 1DJW; -.
DR   PDBsum; 1DJX; -.
DR   PDBsum; 1DJY; -.
DR   PDBsum; 1DJZ; -.
DR   PDBsum; 1MAI; -.
DR   PDBsum; 1QAS; -.
DR   PDBsum; 1QAT; -.
DR   PDBsum; 2ISD; -.
DR   DisProt; DP00055; -.
DR   ProteinModelPortal; P10688; -.
DR   SMR; P10688; 12-130, 158-756.
DR   BioGrid; 246790; 1.
DR   MINT; MINT-245440; -.
DR   STRING; 10116.ENSRNOP00000042824; -.
DR   BindingDB; P10688; -.
DR   ChEMBL; CHEMBL1914273; -.
DR   PhosphoSite; P10688; -.
DR   PaxDb; P10688; -.
DR   PRIDE; P10688; -.
DR   GeneID; 24655; -.
DR   KEGG; rno:24655; -.
DR   UCSC; RGD:3346; rat.
DR   CTD; 5333; -.
DR   RGD; 3346; Plcd1.
DR   eggNOG; NOG149692; -.
DR   HOGENOM; HOG000006871; -.
DR   HOVERGEN; HBG053610; -.
DR   InParanoid; P10688; -.
DR   KO; K05857; -.
DR   PhylomeDB; P10688; -.
DR   BRENDA; 3.1.4.11; 5301.
DR   SABIO-RK; P10688; -.
DR   EvolutionaryTrace; P10688; -.
DR   NextBio; 603990; -.
DR   PRO; PR:P10688; -.
DR   Proteomes; UP000002494; Unplaced.
DR   Genevisible; P10688; RN.
DR   GO; GO:0005829; C:cytosol; IDA:RGD.
DR   GO; GO:0016020; C:membrane; IDA:RGD.
DR   GO; GO:0045121; C:membrane raft; IDA:RGD.
DR   GO; GO:0031966; C:mitochondrial membrane; IDA:RGD.
DR   GO; GO:0005634; C:nucleus; IDA:RGD.
DR   GO; GO:0005509; F:calcium ion binding; IDA:RGD.
DR   GO; GO:0004435; F:phosphatidylinositol phospholipase C activity; IDA:RGD.
DR   GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; IDA:RGD.
DR   GO; GO:0005543; F:phospholipid binding; IDA:RGD.
DR   GO; GO:0004871; F:signal transducer activity; IEA:UniProtKB-KW.
DR   GO; GO:0051480; P:cytosolic calcium ion homeostasis; IMP:RGD.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IDA:RGD.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   GO; GO:0016042; P:lipid catabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0051482; P:positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway; IMP:RGD.
DR   GO; GO:0032962; P:positive regulation of inositol trisphosphate biosynthetic process; IMP:RGD.
DR   GO; GO:0010701; P:positive regulation of norepinephrine secretion; IMP:RGD.
DR   GO; GO:1900274; P:regulation of phospholipase C activity; IMP:RGD.
DR   GO; GO:0010044; P:response to aluminum ion; IEP:RGD.
DR   GO; GO:0051592; P:response to calcium ion; IMP:RGD.
DR   GO; GO:0055093; P:response to hyperoxia; IEP:RGD.
DR   GO; GO:0010243; P:response to organonitrogen compound; IEP:RGD.
DR   GO; GO:0043434; P:response to peptide hormone; IMP:RGD.
DR   GO; GO:0034696; P:response to prostaglandin F; IEP:RGD.
DR   Gene3D; 1.10.238.10; -; 2.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   Gene3D; 3.20.20.190; -; 2.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR018247; EF_Hand_1_Ca_BS.
DR   InterPro; IPR002048; EF_hand_dom.
DR   InterPro; IPR011993; PH-like_dom.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR001192; PI-PLC_fam.
DR   InterPro; IPR028391; PLC-delta1.
DR   InterPro; IPR017946; PLC-like_Pdiesterase_TIM-brl.
DR   InterPro; IPR015359; PLipase_C_EF-hand-like.
DR   InterPro; IPR000909; PLipase_C_PInositol-sp_X_dom.
DR   InterPro; IPR001711; PLipase_C_Pinositol-sp_Y.
DR   PANTHER; PTHR10336; PTHR10336; 1.
DR   PANTHER; PTHR10336:SF80; PTHR10336:SF80; 1.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF09279; EF-hand_like; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00388; PI-PLC-X; 1.
DR   Pfam; PF00387; PI-PLC-Y; 1.
DR   PRINTS; PR00390; PHPHLIPASEC.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00054; EFh; 2.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00148; PLCXc; 1.
DR   SMART; SM00149; PLCYc; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF51695; SSF51695; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00018; EF_HAND_1; 2.
DR   PROSITE; PS50222; EF_HAND_2; 2.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS50007; PIPLC_X_DOMAIN; 1.
DR   PROSITE; PS50008; PIPLC_Y_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Complete proteome; Direct protein sequencing;
KW   Glycoprotein; Hydrolase; Lipid degradation; Lipid metabolism;
KW   Metal-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; Transducer.
FT   CHAIN         1    756       1-phosphatidylinositol 4,5-bisphosphate
FT                                phosphodiesterase delta-1.
FT                                /FTId=PRO_0000088506.
FT   DOMAIN       21    130       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      140    175       EF-hand 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   DOMAIN      176    211       EF-hand 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   DOMAIN      296    440       PI-PLC X-box. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00270}.
FT   DOMAIN      492    609       PI-PLC Y-box. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00271}.
FT   DOMAIN      630    720       C2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   CA_BIND     153    164       1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   CA_BIND     189    200       2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   REGION       30     57       Substrate binding.
FT   ACT_SITE    311    311
FT   ACT_SITE    356    356
FT   METAL       312    312       Calcium 1; catalytic.
FT   METAL       341    341       Calcium 1; catalytic.
FT   METAL       343    343       Calcium 1; catalytic.
FT   METAL       390    390       Calcium 1; catalytic.
FT   METAL       651    651       Calcium 2; via carbonyl oxygen.
FT   METAL       653    653       Calcium 2.
FT   METAL       677    677       Calcium 2.
FT   METAL       706    706       Calcium 3.
FT   METAL       707    707       Calcium 3; via carbonyl oxygen.
FT   METAL       708    708       Calcium 3.
FT   BINDING     438    438       Substrate.
FT   BINDING     440    440       Substrate.
FT   BINDING     522    522       Substrate.
FT   BINDING     549    549       Substrate.
FT   MOD_RES     460    460       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P51178}.
FT   CARBOHYD    191    191       O-linked (GlcNAc).
FT                                {ECO:0000269|PubMed:24098488}.
FT   CARBOHYD    193    193       O-linked (GlcNAc).
FT                                {ECO:0000269|PubMed:24098488}.
FT   VARIANT     412    412       I -> M (in SHR).
FT                                {ECO:0000269|PubMed:1684614}.
FT   VARIANT     423    423       T -> S (in SHR).
FT                                {ECO:0000269|PubMed:1684614}.
FT   VARIANT     463    463       V -> D (in SHR).
FT                                {ECO:0000269|PubMed:1684614}.
FT   VARIANT     668    668       G -> A (in SHR).
FT                                {ECO:0000269|PubMed:1684614}.
FT   MUTAGEN     311    311       H->A: Lowers activity 10000-fold.
FT                                {ECO:0000269|PubMed:9565585}.
FT   MUTAGEN     312    312       N->A: Lowers activity 10000-fold.
FT                                {ECO:0000269|PubMed:9565585}.
FT   MUTAGEN     320    320       L->A: Lowers activity 3-fold.
FT                                {ECO:0000269|PubMed:9565585}.
FT   MUTAGEN     341    341       E->A,H,Q: Lowers activity 200000-fold.
FT                                {ECO:0000269|PubMed:9565585}.
FT   MUTAGEN     343    343       D->A: Lowers activity 1000-fold.
FT                                {ECO:0000269|PubMed:9565585}.
FT   MUTAGEN     343    343       D->R: Lowers activity 100000-fold.
FT                                {ECO:0000269|PubMed:9565585}.
FT   MUTAGEN     356    356       H->A: Lowers activity 1000-fold.
FT                                {ECO:0000269|PubMed:9565585}.
FT   MUTAGEN     360    360       F->A: Lowers activity 4-fold.
FT                                {ECO:0000269|PubMed:9565585}.
FT   MUTAGEN     390    390       E->A,H,K: Lowers activity 1000-fold.
FT                                {ECO:0000269|PubMed:9565585}.
FT   MUTAGEN     390    390       E->Q: Lowers activity 200-fold.
FT                                {ECO:0000269|PubMed:9565585}.
FT   MUTAGEN     438    438       K->A: Lowers activity very slightly.
FT                                {ECO:0000269|PubMed:9565585}.
FT   MUTAGEN     440    440       K->A: No effect on activity towards
FT                                phosphatidylinositol 4-monophosphate.
FT                                Lowers activity 5-fold towards
FT                                phosphatidylinositol 4,5-bisphosphate.
FT                                {ECO:0000269|PubMed:9565585}.
FT   MUTAGEN     522    522       S->A: Lowers activity 10000-fold.
FT                                {ECO:0000269|PubMed:9565585}.
FT   MUTAGEN     549    549       R->A: Lowers activity 600-fold.
FT                                {ECO:0000269|PubMed:9565585}.
FT   MUTAGEN     551    551       Y->A: Lowers activity 600-fold.
FT                                {ECO:0000269|PubMed:9565585}.
FT   MUTAGEN     555    555       W->A: Lowers activity very slightly.
FT                                {ECO:0000269|PubMed:9565585}.
FT   CONFLICT    627    629       RPE -> APK (in Ref. 2; AAP31521).
FT                                {ECO:0000305}.
FT   HELIX        17     24       {ECO:0000244|PDB:1MAI}.
FT   STRAND       26     35       {ECO:0000244|PDB:1MAI}.
FT   STRAND       37     44       {ECO:0000244|PDB:1MAI}.
FT   STRAND       48     53       {ECO:0000244|PDB:1MAI}.
FT   TURN         62     65       {ECO:0000244|PDB:1MAI}.
FT   STRAND       66     68       {ECO:0000244|PDB:1MAI}.
FT   HELIX        69     71       {ECO:0000244|PDB:1MAI}.
FT   STRAND       72     79       {ECO:0000244|PDB:1MAI}.
FT   HELIX        82     87       {ECO:0000244|PDB:1MAI}.
FT   HELIX        93     95       {ECO:0000244|PDB:1MAI}.
FT   STRAND       96    104       {ECO:0000244|PDB:1MAI}.
FT   STRAND      108    111       {ECO:0000244|PDB:1MAI}.
FT   HELIX       115    129       {ECO:0000244|PDB:1MAI}.
FT   STRAND      159    161       {ECO:0000244|PDB:1DJX}.
FT   HELIX       162    170       {ECO:0000244|PDB:1DJX}.
FT   TURN        171    173       {ECO:0000244|PDB:1DJX}.
FT   HELIX       178    180       {ECO:0000244|PDB:1DJX}.
FT   HELIX       181    188       {ECO:0000244|PDB:1DJX}.
FT   STRAND      190    197       {ECO:0000244|PDB:1DJX}.
FT   HELIX       203    208       {ECO:0000244|PDB:1DJX}.
FT   HELIX       212    222       {ECO:0000244|PDB:1DJX}.
FT   STRAND      225    229       {ECO:0000244|PDB:1DJX}.
FT   HELIX       230    239       {ECO:0000244|PDB:1DJX}.
FT   HELIX       248    258       {ECO:0000244|PDB:1DJX}.
FT   HELIX       262    266       {ECO:0000244|PDB:1DJX}.
FT   HELIX       272    280       {ECO:0000244|PDB:1DJX}.
FT   TURN        282    284       {ECO:0000244|PDB:1DJX}.
FT   STRAND      285    287       {ECO:0000244|PDB:1DJX}.
FT   HELIX       289    292       {ECO:0000244|PDB:1DJX}.
FT   HELIX       302    304       {ECO:0000244|PDB:1DJX}.
FT   STRAND      305    307       {ECO:0000244|PDB:1DJX}.
FT   STRAND      309    312       {ECO:0000244|PDB:1DJX}.
FT   STRAND      315    317       {ECO:0000244|PDB:1DJX}.
FT   STRAND      319    321       {ECO:0000244|PDB:1DJX}.
FT   HELIX       326    334       {ECO:0000244|PDB:1DJX}.
FT   STRAND      339    345       {ECO:0000244|PDB:1DJX}.
FT   HELIX       348    350       {ECO:0000244|PDB:1DJX}.
FT   STRAND      353    355       {ECO:0000244|PDB:1QAS}.
FT   TURN        357    360       {ECO:0000244|PDB:1DJY}.
FT   HELIX       366    376       {ECO:0000244|PDB:1DJX}.
FT   TURN        377    379       {ECO:0000244|PDB:1DJX}.
FT   STRAND      385    392       {ECO:0000244|PDB:1DJX}.
FT   HELIX       395    409       {ECO:0000244|PDB:1DJX}.
FT   HELIX       410    412       {ECO:0000244|PDB:1DJX}.
FT   TURN        428    433       {ECO:0000244|PDB:1DJX}.
FT   STRAND      435    439       {ECO:0000244|PDB:1DJX}.
FT   HELIX       490    493       {ECO:0000244|PDB:1DJX}.
FT   STRAND      496    502       {ECO:0000244|PDB:1DJX}.
FT   STRAND      509    514       {ECO:0000244|PDB:1DJX}.
FT   STRAND      519    524       {ECO:0000244|PDB:1DJX}.
FT   HELIX       525    545       {ECO:0000244|PDB:1DJX}.
FT   STRAND      548    551       {ECO:0000244|PDB:1DJX}.
FT   HELIX       565    568       {ECO:0000244|PDB:1DJX}.
FT   TURN        569    571       {ECO:0000244|PDB:1DJX}.
FT   STRAND      574    577       {ECO:0000244|PDB:1DJX}.
FT   HELIX       584    594       {ECO:0000244|PDB:1DJX}.
FT   HELIX       596    598       {ECO:0000244|PDB:1DJX}.
FT   STRAND      600    603       {ECO:0000244|PDB:1DJX}.
FT   HELIX       606    609       {ECO:0000244|PDB:1DJX}.
FT   STRAND      629    640       {ECO:0000244|PDB:1DJX}.
FT   HELIX       644    646       {ECO:0000244|PDB:1QAT}.
FT   STRAND      648    650       {ECO:0000244|PDB:1DJX}.
FT   STRAND      654    663       {ECO:0000244|PDB:1DJX}.
FT   HELIX       664    666       {ECO:0000244|PDB:1DJX}.
FT   STRAND      668    671       {ECO:0000244|PDB:1DJX}.
FT   STRAND      679    681       {ECO:0000244|PDB:1DJX}.
FT   STRAND      683    693       {ECO:0000244|PDB:1DJX}.
FT   HELIX       695    697       {ECO:0000244|PDB:1DJX}.
FT   STRAND      699    706       {ECO:0000244|PDB:1DJX}.
FT   STRAND      709    711       {ECO:0000244|PDB:1DJX}.
FT   STRAND      714    722       {ECO:0000244|PDB:1DJX}.
FT   HELIX       723    725       {ECO:0000244|PDB:1DJX}.
FT   STRAND      729    736       {ECO:0000244|PDB:1DJX}.
FT   STRAND      742    755       {ECO:0000244|PDB:1DJX}.
SQ   SEQUENCE   756 AA;  85962 MW;  E33F2313AC81E9F9 CRC64;
     MDSGRDFLTL HGLQDDPDLQ ALLKGSQLLK VKSSSWRRER FYKLQEDCKT IWQESRKVMR
     SPESQLFSIE DIQEVRMGHR TEGLEKFARD IPEDRCFSIV FKDQRNTLDL IAPSPADAQH
     WVQGLRKIIH HSGSMDQRQK LQHWIHSCLR KADKNKDNKM NFKELKDFLK ELNIQVDDGY
     ARKIFRECDH SQTDSLEDEE IETFYKMLTQ RAEIDRAFEE AAGSAETLSV ERLVTFLQHQ
     QREEEAGPAL ALSLIERYEP SETAKAQRQM TKDGFLMYLL SADGNAFSLA HRRVYQDMDQ
     PLSHYLVSSS HNTYLLEDQL TGPSSTEAYI RALCKGCRCL ELDCWDGPNQ EPIIYHGYTF
     TSKILFCDVL RAIRDYAFKA SPYPVILSLE NHCSLEQQRV MARHLRAILG PILLDQPLDG
     VTTSLPSPEQ LKGKILLKGK KLGGLLPAGG ENGSEATDVS DEVEAAEMED EAVRSQVQHK
     PKEDKLKLVP ELSDMIIYCK SVHFGGFSSP GTSGQAFYEM ASFSESRALR LLQESGNGFV
     RHNVSCLSRI YPAGWRTDSS NYSPVEMWNG GCQIVALNFQ TPGPEMDVYL GCFQDNGGCG
     YVLKPAFLRD PNTTFNSRAL TQGPWWRPER LRVRIISGQQ LPKVNKNKNS IVDPKVIVEI
     HGVGRDTGSR QTAVITNNGF NPRWDMEFEF EVTVPDLALV RFMVEDYDSS SKNDFIGQST
     IPWNSLKQGY RHVHLLSKNG DQHPSATLFV KISIQD
//
